Professor Walter Van Dyck contributes to business model for a European-wide health information ecosystem
Vlerick professor Walter Van Dyck has been appointed by the Innovative Medicines Initiative (IMI) as a subject matter expert advising on the design and use of future health care business models enhancing biopharmaceutical R&D productivity and patient interaction in an era of personalised medicine.
The Innovative Medicines Initiative (IMI), a €2 billion euro budget joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients.
Professor Walter Van Dyck is honoured by this appointment. “On a personal level this is a recognition of my expertise in the field of healthcare business model design encompassing collaboration between life sciences companies, hospitals, and health management organisations. From a broader perspective on EU level this project is a key step in the transformation from classical to individualised medicine enabled by digitising humans.”
Walter will function as the business modelling expert in a team of medical and biopharmaceutical researchers and health IT experts. “The goals is to design a business model for a European-wide health information ecosystem allowing researchers to link on an immense scale patient health records, genomic data, survey data, imaging and biosensor data, and social, environmental and economic data. This will speed up the development of complex individualised medicines and mobile health applications initially in the fields of obesity and Alzheimer’s disease.”